LAS VEGAS, March 22, 2021 /PRNewswire/ -- DelveInsight's "Polymyalgia Rheumatica (PMR) Market" report provides a thorough comprehension of the Polymyalgia Rheumatica, historical and forecasted ...

New York, May 29, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Reports Insights, the polymyalgia rheumatica treatment market is poised for strong expansion and is expected to reach USD 263 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an ...

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica ...

For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is ...

All About Polymyalgia Rheumatica and Temporal Arteritis: From Symptoms to Treatments: By Shreoshree Chakrabarty Polymyalgia rheumatica (PMR) and temporal arteritis, also known as giant cell arteritis ...

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study ...

Polymyalgia rheumatica primarily affects persons of northern European descent and has an annual incidence of about 50 per 100,000 adults older than 50 years. The condition is believed to be increasing ...

Polymyalgia rheumatica (PMR) is an inflammatory disorder of unknown aetiology that can be extremely disabling when active. Glucocorticoids are currently the therapy of choice for patients with PMR, ...

In this article, Lally and colleagues present the results of an open-label trial of the anti-interleukin (IL)-6 receptor agent tocilizumab in 10 patients with isolated polymyalgia rheumatica (PMR).

Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes severe muscle pain, muscle stiffness, muscle spasms and cramping on both sides of the body, particularly in the shoulders, neck, ...

The US Food and Drug Administration (FDA) approved sarilumab (Kevzara) today for the treatment of polymyalgia rheumatica (PMR) in adults who have had an inadequate response to corticosteroids or could ...